糖尿病领域研发态势分析
收稿日期: 2022-08-15
修回日期: 2022-09-30
网络出版日期: 2022-10-12
基金资助
国家自然科学基金专项项目(L1924031)
Progress on research and development in diabetes mellitus
Received date: 2022-08-15
Revised date: 2022-09-30
Online published: 2022-10-12
Supported by
the National Natural Science Foundation of China(L1924031)
糖尿病(diabetes mellitus)是由胰岛素分泌缺乏和/或胰岛素抵抗引起的以高血糖为特征的一类代谢性疾病,已成为威胁全球人类健康的重大疾病之一。本文从论文、专利、药物、产业发展等方面分析了糖尿病领域国内外研发态势,旨在为我国糖尿病领域研究及相关产业发展提供决策参考。结果表明,论文发表方面,糖尿病领域研究的论文数量稳步增长,研究热点主要包括并发症及流行病学研究;技术开发方面,比利时杨森制药、美国礼来制药、德国勃林格殷格翰公司等大型制药企业在糖尿病诊断、治疗、管理等方面积极探索;药物研发方面,截至2022年3月23日,已有207个药物上市,还有大量药物处于临床前及临床阶段;产业发展方面,国内外市场潜力巨大,糖尿病数字化管理快速发展。我国在糖尿病研究和技术开发方面拥有一定的实力,未来需要采取措施加强研究成果转化与产品开发,以满足我国庞大的糖尿病诊疗与管理需求。
张丽雯, 阮梅花, 刘加兰, 贺彩红, 于建荣 . 糖尿病领域研发态势分析[J]. 遗传, 2022 , 44(10) : 824 -839 . DOI: 10.16288/j.yczz.22-272
Diabetes mellitus is a kind of metabolic disease characterized by hyperglycemia resulting from insulin insufficiency and insulin resistance. It has become one of the major diseases threatening human health. In this paper, we analyze the current R&D status of diabetes from the aspects of papers, patents, drugs and industrial development. The results show that scientific outcomes are increasing steadily and the hot topics are diabetic complications and epidemiological research. In terms of technology development, large pharmaceutical companies, such as Janssen Pharmaceutical, Lilly pharmaceutical, Boehringer Ingelheim, are actively engaged in diagnosis, treatment and management of diabetes. By March 23 2022, 207 drugs have been launched and a large number of candidate drugs are in the pre-clinical and clinical stage. In terms of industrial development, the potential diabetes market is huge and the digital management of diabetes is developing rapidly. China has certain strength in diabetes research and development. In the future, measures should be taken to strengthen the transformation of research outcomes, and promote product development to meet China’s huge needs of diabetes cares.
| [1] | Endocrine Metabolic Branch of Chinese Medical Doctor Association, National Clinical Medical Research Center for Metabolic Diseases. Classification of diabetes mellitus in China: an expert consensus statement. Chin J Diabetes, 2022, 14(2): 120-139. |
| [1] | 中国医师协会内分泌代谢科医师分会, 国家代谢性疾病临床医学研究中心. 糖尿病分型诊断中国专家共识. 中华糖尿病杂志, 2022, 14(2): 120-139. |
| [2] | International Diabetes Federation.IDF Diabetes Atlas 10th edition. [2022-04-20]. . |
| [3] | Nature Milestones in Diabetes. (2021-10-29)[2022-03-20]. . |
| [4] | Ma N, Zhu YN. Pathogenesis and recent research progress of gestational diabetes mellitus. Smart Healthcare, 2019, 5(22): 62-64, 67. |
| [4] | 马宁, 朱永宁. 妊娠期糖尿病的发病机制和最新研究进展. 智慧健康, 2019, 5(22): 62-64, 67. |
| [5] | Song D, Ran LY, Jiang RJ, Wu YJ.Animal models in diabetes mellitus research. Chin J Comp Med, 2016, 26(9): 83-87. |
| [5] | 宋丹, 冉丽媛, 姜如娇, 吴英杰. 糖尿病研究中的动物模型进展. 中国比较医学杂志, 2016, 26(9): 83-87. |
| [6] | Marek-Trzonkowska N, Myśliwiec MŁ, Dobyszuk A, Grabowska M, Techmańska I, Juścińskad J, Wujtewicz MA, Witkowski P, Młynarski W, Balcerska A, Myśliwska J, Trzonkowski P. Administration of CD4+ CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care, 2012, 35(9): 1817-1820. |
| [7] | Marek-Trzonkowska N, Myśliwiec ML, Dobyszuk A, Grabowska M, Derkowskab I, Juścińskad J, Owczuke R, Szadkowskaf A, Witkowskig P, Młynarskif W, Jarosz- Choboth P, Bossowskii A, Sieberta J, Trzonkowskic P. Therapy of type 1 diabetes with CD4+ CD25highCD127- regulatory T cells prolongs survival of pancreatic islets— results of one year follow-up. Clin Immunol, 2014, 153(1): 23-30. |
| [8] | Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol, 2017, 5(4): 251-260. |
| [9] | Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus, 2021, 13(4): 315-409. |
| [9] | 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版). 中华糖尿病杂志, 2021, 13(4): 315-409. |
| [10] | El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017, 389(10067): 369-380. |
| [11] | Cai C, Jia WP. Application and challenge of artificial intelligence in continuous Diabetes management. Bull Natl Nat Sci Found China, 2021, 35(1): 104-109. |
| [11] | 蔡淳, 贾伟平. 人工智能在糖尿病全程健康管理的应用与挑战. 中国科学基金, 2021, 35(1): 104-109. |
| [12] | Shen S, Liu HF, Xu XY, Yu JN. Research progress of drugs for Diabetic complication treatment. Chin Pharm Aff, 2012, 26(8): 906-910. |
| [12] | 申升, 刘宏飞, 徐希明, 余江南. 治疗糖尿病并发症药物的研究进展. 中国药事, 2012, 26(8): 906-910. |
| [13] | Alanazi AZ, Mohany M, Alasmari F, Mothana RAA, Alshehri AOA, Alhazzani K, Ahmed MM, Al-Rejaie SS. Amelioration of diabetes-induced nephropathy by loranthus regularis: implication of oxidative stress, inflammation and hyperlipidaemia. Appl Sci, 2021, 11(10): 4548. |
| [14] | Kotova JA, Zuikova AA, Pashko AN, Strahova NV, Krasnorutskaya ON, Shevzova VI, Esina EY. Markers of endothelial damage, inflammation, oxidative and cellular stress in patients with coronary artery disease and type 2 diabetes. Int J Biomed, 2020, 10(2): 104-107. |
| [15] | Gupta A, Nayan N, Nair R, Kumar K, Joshi A, Sharma S, Singh J, Kapoor R. Diabetes mellitus and hypertension increase risk of death in novel corona virus patients irrespective of age: a prospective observational study of co-morbidities and COVID-19 from India. SN Compr Clin Med, 2021, 3(4): 937-944. |
| [16] | Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes, 2020, 12(12): 895-908. |
| [17] | Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Pediatric Diabetes Consortium. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabet Med, 2020, 37(5): 863-867. |
| [18] | Mobley-Bukstein W, Reece SM, Hebdon K. Special considerations in the management and education of older persons with diabetes. ADCES Pract, 2021, 9(4): 30-42. |
| [19] | Minschart C, De Weerdt K, Elegeert A, Van Crombrugge P, Moyson C, Verhaeghe J, Vandeginste S, Verlaenen H, Vercammen C, Maes T, Dufraimont E, De Block C, Jacquemyn Y, Mekahli F, De Clippel K, Van Den Bruel A, Loccufier A, Laenen A, Devlieger R, Mathieu C, Benhalima K. Antenatal depression and risk of gestational diabetes, adverse pregnancy outcomes, and postpartum quality of life. J Clin Endocrinol Metab, 2021, 106(8): e3110-e3124. |
| [20] | Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol, 2021, 20(1): 14. |
| [21] | Math L, Fatima R. Adaptive machine learning classification for diabetic retinopathy. Multimedia Tools Appl, 2021, 80: 5173-5186. |
| [22] | McGrail S. Eli Lilly takes on digital diabetes care management. (2021-05-12)[2022-05-15]. . |
| [23] | Sanofi. A broad range of innovative medicines. (2019- 06-14)[2022-05-13]. . |
| [24] | Novo Nordisk. R&D pipeline. [2022-05-15]. . |
| [25] | AstraZeneca. Pipeline. (2022-03-22)[2022-05-15]. . |
| [26] | 通化东宝药业股份有限公司. 企业简介. [2022-05-15]. . |
| [27] | 甘李药业股份有限公司. 企业介绍. [2022-05-15]. . |
| [28] | 联邦制药国际控股有限公司. 集团简介. [2022-05-15]. . |
| [29] | 三生制药. [2022-05-15]. . |
| [30] | 华经情报网.2021-2026 年中国糖尿病药品市场供需现状及投资战略研究报告. (2021-01-12)[2022-06-15]. . |
| [31] | Yuan S, Gill D, Giovannucci EL, Larsson SC. Obesity type 2 diabetes, lifestyle factors, and risk of gallstone disease: a mendelian randomization investigation. Clin Gastroenterol Hepatol, 2022, 20(3): e529-e537. |
| [32] | Repple J, König A, de Lange SC, Opel N, Redlich R, Meinert S, Grotegerd D, Mauritz M, Hahn T, Borgers T, Leehr EJ, Winter N, Goltermann J, Enneking V, Fingas SM, Lemke H, Waltemate L, Dohm K, Richter M, Mehler DMA, Holstein V, Gruber M, Nenadic I, Krug A, Brosch K, Schmitt S, Stein F, Meller T, Jansen A, Steinsträter O, Amare AT, Kircher T, Baune BT, van den Heuvel MP, Dannlowski U. Association between genetic risk for type 2 diabetes and structural brain connectivity in major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging, 2022, 7(3): 333-340. |
| [33] | Cinkajzlová A, Mráz M, Haluzík M. Adipose tissue immune cells in obesity, type 2 diabetes mellitus and cardiovascular diseases. J Endocrinol, 2021, 252(1): R1-R22. |
| [34] | 华经情报网.2020年糖尿病药物行业现状及趋势分析, 降糖药物将加快升级换代. (2021-09-09)[2022-03-24]. . |
| [35] | Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet, 2022, 399(10322): 394-405. |
| [36] | Guo LX. 2021 annual review of major progress in diabetes. Chin J Diabetes Mellitus, 2022, 14(1): 1-8. |
| [36] | 郭立新. 2021年糖尿病领域年度重大进展回顾. 中华糖尿病杂志, 2022, 14(1): 1-8. |
| [37] | 动脉网. 智能设备成为糖尿病数字化管理基本前提, 关键创新点有哪些?(2021-01-06)[2022-03-24]. . |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
